Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS-CoV-2 Omicron in patients with haematological malignancies: A national prospective cohort study

Information regarding the protective anti-SARS-CoV-2 antibody levels and the effectiveness of the mRNA vaccines against the Omicron variant in patients with haematological malignancies is limited. We prospectively followed two times BNT162b2 vaccinated oncohaematological patients (n = 1010) without...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2024-02, Vol.204 (2), p.497-506
Hauptverfasser:	Kevličius, Lukas, Šablauskas, Karolis, Maneikis, Kazimieras, Juozapaitė, Dovilė, Ringelevičiūtė, Ugnė, Vaitekėnaitė, Vilmantė, Davainienė, Birutė, Daukėlaitė, Guoda, Vasilevska, Dominika, Stoškus, Mindaugas, Narkevičiūtė, Ieva, Sivickienė, Violeta, Rudaitis, Kęstutis, Minkauskas, Mantas, Naumovas, Daniel, Beinortas, Tumas, Griškevičius, Laimonas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine COVID-19 COVID-19 vaccines Drug dosages Hematologic Neoplasms Hematology Humans Immunogenicity Immunoglobulin G Infections Malignancy mRNA mRNA Vaccines Prospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Information regarding the protective anti-SARS-CoV-2 antibody levels and the effectiveness of the mRNA vaccines against the Omicron variant in patients with haematological malignancies is limited. We prospectively followed two times BNT162b2 vaccinated oncohaematological patients (n = 1010) without prior COVID-19 for PCR-confirmed breakthrough infections during the Alpha/Delta and the Omicron phases of the pandemic. Anti-S1-IgG levels were longitudinally monitored in patients who had received the third (booster) vaccine dose. Patients with anti-S1-IgG levels
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.19126